Hitachi Aloka, the innovator in ultrasound is the longest operating ultrasound company in the world with its international headquarters located in Tokyo, Japan and U.S. headquarters in Wallingford, CT. The history of Hitachi Aloka began in 1950 when the medical equipment department of Japan Radio Company became the independent company, Medical and Physical Institute Co., Ltd. In 1960, Hitachi Aloka developed the world’s first commercially available diagnostic ultrasound system.
The Massachusetts Prostate Cancer Coalition (MPCC) educates, connects, and supports men-at-risk, newly diagnosed individuals, survivors, and their families. It also connects organizations and professionals in Massachusetts that seek to conquer and cure prostate cancer.
Royal Philips of the Netherlands is a diversified technology company, focused on improving people’s lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle and Lighting. Philip’s commitment is to deliver new healthcare and lighting technologies, as well as innovative and locally relevant consumer products that make a real difference to our customers, consumers and stakeholders across the globe.
Invivo is a business of Royal Philips (NYSE: PHG; AEX: PHIA) and has an over 20-year history as the pioneer of progressive MRI coils, advanced clinical visualization systems, and MRI-compatible interventional devices. To learn more, please visithttp://www.invivocorp.com/
Siemens Healthineers is committed to becoming the trusted partner of healthcare providers worldwide, enabling them to improve patient outcomes while reducing costs. Driven by our long legacy of engineering excellence and our pioneering approach to developing the latest advancements, we are a global leader in medical imaging, laboratory diagnostics, clinical IT, and services. usa.siemens.com/Healthineers
Genomic Health is the world’s leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today. The company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of massive amounts of genomic data into clinically-actionable results for treatment planning throughout the cancer patient’s journey, from diagnosis to treatment selection and monitoring.
Myriad is focused on revolutionizing patient care through the discovery, development and marketing of transformative molecular diagnostic tests that address pressing clinical needs across multiple medical specialties. Myriad has invested heavily in educating patients and healthcare professionals about the role genes and proteins play in disease. Today, Myriad is expanding its reach and increasing its impact on patient care by introducing new molecular diagnostic and companion diagnostic tests for a growing number of diseases.
ScanMed‘s mission is to out produce its competitors in terms of creating high quality imaging antennas for the MRI marketplace; repairing and restoring the world’s antennas in less time with higher reliability; and exceeding the demands of our customers: the OEMs, ISOs, hospitals and imaging facilities while meeting regulatory requirements. When surgeons, radiologists, and medical researchers need precise and reliable image data to make lifesaving decisions, they turn to ScanMed.
Steward Health Care System is a community-based health care organization with 3,000 physicians, 10 hospital campuses, and 24 affiliated urgent care provider locations. Steward is committed to providing the highest quality of patient care in the communities where our patients live.Steward is widely recognized as a national leader in implementing a new model of integrated health care delivery. Steward’s model takes care of patients from wellness and care management all the way through their end of life.
Blue Earth Diagnostics is a molecular imaging diagnostics company focused on the development and commercialization of novel PET imaging agents to inform clinical management and guide care for cancer patients in areas of unmet medical need. Formed in 2014, Blue Earth Diagnostics is led by recognized experts in the clinical development and commercialization of innovative nuclear medicine products. The Company’s first approved and commercially available product is AxuminTM (fluciclovine F 18), a novel molecular imaging agent for use in PET imaging to detect and localize prostate cancer in men experiencing suspected biochemical recurrence. Blue Earth Diagnostics Inc. of Burlington, Mass., is the wholly-owned U.S. subsidiary of U.K.-based Blue Earth Diagnostics Ltd. The Company is funded by Syncona LLP, an independent subsidiary of the Wellcome Trust. For more information, visit: www.blueearthdx.com.
Desert Medical Imaging (DMI) is a physician owned, multimodality imaging center committed to providing the newest technology in the industry in an environment that is focused on excellent patient care. Desert Medical Imaging will provide the highest quality patient care possible in an outpatient imaging center.
The GenomeDx mission is to reimagine the use of genomic information to transform and improve cancer patient care. By analyzing large amounts of complex data, GenomeDx is developing tools that simplify the way patient care is managed. We’re increasing the efficiency of practice management, optimizing decision-making related to patient care, and improving outcomes for our patients. Through the capture, analysis and exchange of genomic information, GenomeDx is working to change the way cancer is understood.
KOELIS‘ mission: to address prostate cancer by developing innovative software and imaging devices for urologists. For the first time 3D Ultrasound, Elastic Image Fusion and Organ-Based Tracking® are combined into an easy to use platform that enables urologists to document 3D prostate biopsy maps and to target suspicious lesions in all patients.
LabCorp provides leading-edge medical laboratory tests and services through a national network of primary clinical laboratories and specialty testing laboratories.With scientific expertise in esoteric testing, genomics, and clinical and anatomic pathology, LabCorp processes tests on approximately 470,000 specimens each day, applying advances in medicine and science to laboratory testing.
Tokai Pharmaceuticals is focused on developing and delivering innovative therapies that provide hope and healing for patients living with cancer. Our lead product candidate is galeterone, a highly-selective, oral small molecule that is currently being developed for patients with metastatic, castration-resistant prostate cancer whose prostate tumor cells express the AR-V7 splice variant, which is a truncated form of the androgen receptor. We have global development and commercial rights to galeterone. Our pipeline also includes an ongoing program to identify and develop novel compounds designed to disrupt androgen receptor signaling through enhanced androgen receptor degradation.